AAD VMX 2021: Long-Term Open-Label Extension Study Reveals Durability of Tralokinumab for Atopic Dermatitis
Both efficacy and safety were maintained for up to 2 years of treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.